Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934...
Annual Report filed on Form 20-F
Filed with ASX · · 202 pages · English
Summary by 6ix AI
It highlights the company's ongoing challenges, including a history of operating losses and the need for additional financing to support its research and development efforts. The report also discusses the status of its product candidates and the potential impact of regulatory approvals on future revenue generation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Immutep
- Quality of Life Data from EFTISARC-NEO presented at ESMO
- Late-Breaking Abstract on IMP761 to be presented at ACR 2026
- 2026 Annual General Meeting and Key Dates
- Immutep & Monash Secure Further ARC Funding for LAG-3
- Immutep Regains Compliance with Nasdaq
Later from Immutep
- Annual Report to shareholders
- Appendix 4G and Corporate Governance Statement
- Notice of Annual General Meeting/Proxy Form
- Immutep Receives A$2.16 million French R&D Tax Incentive
- Immutep Quarterly Activities Report and Appendix 4C
